METHODS FOR TREATING METABOLIC DISORDERS USING FGF
The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidaemia, obesity, and fatty liver.
1 . A pharmaceutical composition for treating a metabolic disorder in an individual comprising an FGF-1 compound.
2 . The composition of claim 1 , wherein the FGF-1 compound is a functional fragment of FGF-1.
3 . The composition of claim 1 , wherein the FGF-1 compound is a functional analog of FGF-1.
4 . The composition of claim 1 , wherein the composition is formulated for intravenous administration.
5 . The composition of claim 1 , wherein the composition is formulated for subcutaneous administration.
6 . The composition of claim 1 , wherein the metabolic disorder is selected from elevated blood glucose, impaired glucose tolerance, insulin resistance, type II diabetes, obesity, elevated percent body fat, and fatty liver disease.
7 . The composition of claim 1 , wherein the dose of the FGF-1 compound in the composition is equivalent to 0.01-1 mg FGF-1 per kg body weight.
8 . A method for treating a metabolic disorder in an individual, comprising administering an FGF-1 compound to the individual, thereby treating the metabolic disorder.
9 . The method of claim 8 , wherein the metabolic disorder is selected from elevated blood glucose, impaired glucose tolerance, insulin resistance, type II diabetes, obesity, elevated percent body fat, and fatty liver disease.
10 . The method of claim 8 , wherein the metabolic disorder is elevated percent body fat or obesity.
11 . The method of claim 8 , wherein the metabolic disorder is selected from elevated blood glucose, impaired glucose tolerance, and insulin resistance.
12 . The method of claim 8 , wherein the metabolic disorder is type II diabetes.
13 . The method of claim 8 , wherein the metabolic disorder is fatty liver disease.
14 . The method of claim 8 , wherein the FGF-1 compound is administered intravenously.
15 . The method of claim 8 , wherein the FGF-1 compound is administered subcutaneously.
16 . The method of claim 8 , wherein the FGF-1 compound is administered in combination with an additional therapeutic compound.
17 . The method of claim 8 , wherein the FGF-1 compound is a functional fragment of FGF-1.
18 . The method of claim 8 , wherein the FGF-1 compound is a functional analog of FGF-1.
19 . The method of claim 8 , wherein the FGF-1 compound is administered at a dose equivalent to 0.01-1 mg FGF-1 per kg body weight.
20 . The method of claim 8 , wherein the FGF-1 compound is administered once per day or less.